Cargando…

Letrozole Supplementation and the Increased Risk of Elevated Progesterone Levels on Trigger Day

Although using letrozole (LE) during in vitro fertilisation and intracytoplasmic sperm injection (IVF/ICSI) has many advantages, it remains unclear whether LE induces an increase in progestogen during the late follicular phase. The objective of this study was to investigate whether progesterone leve...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Rongju, Zhou, Liling, Chen, Xuemei, He, Hongmei, Cai, Zhaowei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359123/
https://www.ncbi.nlm.nih.gov/pubmed/35957830
http://dx.doi.org/10.3389/fendo.2022.904089
_version_ 1784764071336214528
author Liu, Rongju
Zhou, Liling
Chen, Xuemei
He, Hongmei
Cai, Zhaowei
author_facet Liu, Rongju
Zhou, Liling
Chen, Xuemei
He, Hongmei
Cai, Zhaowei
author_sort Liu, Rongju
collection PubMed
description Although using letrozole (LE) during in vitro fertilisation and intracytoplasmic sperm injection (IVF/ICSI) has many advantages, it remains unclear whether LE induces an increase in progestogen during the late follicular phase. The objective of this study was to investigate whether progesterone levels increased under antagonist protocols supplemented with LE on the trigger day using a retrospective cohort study. The study included 1,133 women who underwent IVF/ICSI cycles from January 2018 to June 2020. After propensity score matching (PSM) for baseline characteristics, 266 patients with gonadotropin-releasing hormone-antagonist (GnRH-ant) were matched to 266 patients with letrozole + GnRH-ant (LE GnRH-ant) (PSM 1 cohort), and 283 patients with gonadotropin-releasing hormone-agonist (GnRH-a) were matched to 283 patients with LE GnRH-ant (PSM 2 cohort). In the PSM 1 cohort, patients in the LE GnRH-a group presented higher progesterone levels (1.22 ± 0.95 ng/mL vs 0.86 ± 0.60 ng/mL, P < 0.001), with a higher proportion of patients with progesterone level > 1.5 ng/mL (24.81% vs 7.52%, P < 0.001). In PSM 2 cohort, patients in the LE GnRH-a group presented higher progesterone levels on trigger day (1.23 ± 0.91 ng/mL vs 0.98 ± 0.61 ng/mL, P < 0.001), with a higher proportion of patients with progesterone level > 1.5 ng/mL (25.45% vs 12.70%, P < 0.001). In the PSM 1 cohort, progesterone levels on the trigger day increased by 0.05 ng/mL, with an increase in every retrieved oocyte in the LE GnRH-ant group (β 0.05 ng/mL [95% CI 0.04, 0.06], P < 0.001), whereas an increase of 0.02 ng/mL was observed in the GnRH-ant group (β 0.02 ng/mL [95% CI 0.01, 0.03], P < 0.001), with P for interaction being 0.0018. In the PSM 2 cohort, progesterone levels on the trigger day increased by 0.05 ng/mL with an increase in every retrieved oocyte in the LE GnRH-ant group (β 0.05 ng/mL [95% CI 0.04, 0.06], P < 0.001), whereas an increase of 0.02 ng/mL was observed in the GnRH-a group (β 0.02 ng/mL [95% CI 0.01, 0.03], P < 0.001), with P for interaction being 0.0002. LE supplementation on the antagonist protocols may increase progesterone levels in the late follicular stage.
format Online
Article
Text
id pubmed-9359123
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93591232022-08-10 Letrozole Supplementation and the Increased Risk of Elevated Progesterone Levels on Trigger Day Liu, Rongju Zhou, Liling Chen, Xuemei He, Hongmei Cai, Zhaowei Front Endocrinol (Lausanne) Endocrinology Although using letrozole (LE) during in vitro fertilisation and intracytoplasmic sperm injection (IVF/ICSI) has many advantages, it remains unclear whether LE induces an increase in progestogen during the late follicular phase. The objective of this study was to investigate whether progesterone levels increased under antagonist protocols supplemented with LE on the trigger day using a retrospective cohort study. The study included 1,133 women who underwent IVF/ICSI cycles from January 2018 to June 2020. After propensity score matching (PSM) for baseline characteristics, 266 patients with gonadotropin-releasing hormone-antagonist (GnRH-ant) were matched to 266 patients with letrozole + GnRH-ant (LE GnRH-ant) (PSM 1 cohort), and 283 patients with gonadotropin-releasing hormone-agonist (GnRH-a) were matched to 283 patients with LE GnRH-ant (PSM 2 cohort). In the PSM 1 cohort, patients in the LE GnRH-a group presented higher progesterone levels (1.22 ± 0.95 ng/mL vs 0.86 ± 0.60 ng/mL, P < 0.001), with a higher proportion of patients with progesterone level > 1.5 ng/mL (24.81% vs 7.52%, P < 0.001). In PSM 2 cohort, patients in the LE GnRH-a group presented higher progesterone levels on trigger day (1.23 ± 0.91 ng/mL vs 0.98 ± 0.61 ng/mL, P < 0.001), with a higher proportion of patients with progesterone level > 1.5 ng/mL (25.45% vs 12.70%, P < 0.001). In the PSM 1 cohort, progesterone levels on the trigger day increased by 0.05 ng/mL, with an increase in every retrieved oocyte in the LE GnRH-ant group (β 0.05 ng/mL [95% CI 0.04, 0.06], P < 0.001), whereas an increase of 0.02 ng/mL was observed in the GnRH-ant group (β 0.02 ng/mL [95% CI 0.01, 0.03], P < 0.001), with P for interaction being 0.0018. In the PSM 2 cohort, progesterone levels on the trigger day increased by 0.05 ng/mL with an increase in every retrieved oocyte in the LE GnRH-ant group (β 0.05 ng/mL [95% CI 0.04, 0.06], P < 0.001), whereas an increase of 0.02 ng/mL was observed in the GnRH-a group (β 0.02 ng/mL [95% CI 0.01, 0.03], P < 0.001), with P for interaction being 0.0002. LE supplementation on the antagonist protocols may increase progesterone levels in the late follicular stage. Frontiers Media S.A. 2022-07-25 /pmc/articles/PMC9359123/ /pubmed/35957830 http://dx.doi.org/10.3389/fendo.2022.904089 Text en Copyright © 2022 Liu, Zhou, Chen, He and Cai https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Liu, Rongju
Zhou, Liling
Chen, Xuemei
He, Hongmei
Cai, Zhaowei
Letrozole Supplementation and the Increased Risk of Elevated Progesterone Levels on Trigger Day
title Letrozole Supplementation and the Increased Risk of Elevated Progesterone Levels on Trigger Day
title_full Letrozole Supplementation and the Increased Risk of Elevated Progesterone Levels on Trigger Day
title_fullStr Letrozole Supplementation and the Increased Risk of Elevated Progesterone Levels on Trigger Day
title_full_unstemmed Letrozole Supplementation and the Increased Risk of Elevated Progesterone Levels on Trigger Day
title_short Letrozole Supplementation and the Increased Risk of Elevated Progesterone Levels on Trigger Day
title_sort letrozole supplementation and the increased risk of elevated progesterone levels on trigger day
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359123/
https://www.ncbi.nlm.nih.gov/pubmed/35957830
http://dx.doi.org/10.3389/fendo.2022.904089
work_keys_str_mv AT liurongju letrozolesupplementationandtheincreasedriskofelevatedprogesteronelevelsontriggerday
AT zhouliling letrozolesupplementationandtheincreasedriskofelevatedprogesteronelevelsontriggerday
AT chenxuemei letrozolesupplementationandtheincreasedriskofelevatedprogesteronelevelsontriggerday
AT hehongmei letrozolesupplementationandtheincreasedriskofelevatedprogesteronelevelsontriggerday
AT caizhaowei letrozolesupplementationandtheincreasedriskofelevatedprogesteronelevelsontriggerday